Recursion Pharmaceuticals (NASDAQ:RXRX) Earns Buy Rating from Needham & Company LLC

Recursion Pharmaceuticals (NASDAQ:RXRX)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a report issued on Thursday,Benzinga reports. They currently have a $8.00 price target on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 117.98% from the stock’s current price.

A number of other brokerages have also recently issued reports on RXRX. Bank of America decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday. Morgan Stanley set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. UBS Group set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Finally, JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Trading Down 2.7%

RXRX stock opened at $3.67 on Thursday. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -2.48 and a beta of 0.95. The business has a fifty day simple moving average of $4.18 and a 200-day simple moving average of $4.70. Recursion Pharmaceuticals has a 52 week low of $2.98 and a 52 week high of $7.89.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.07. The firm had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $24.56 million. Recursion Pharmaceuticals had a negative return on equity of 66.70% and a negative net margin of 863.37%.The firm’s revenue for the quarter was up 671.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.53) earnings per share. On average, equities research analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 220,000 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total value of $924,000.00. Following the transaction, the director owned 6,429,863 shares in the company, valued at $27,005,424.60. The trade was a 3.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Ben R. Taylor sold 21,383 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $4.18, for a total transaction of $89,380.94. Following the completion of the transaction, the chief financial officer directly owned 761,550 shares of the company’s stock, valued at approximately $3,183,279. The trade was a 2.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 819,212 shares of company stock valued at $3,523,950. Corporate insiders own 8.43% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after purchasing an additional 7,407,606 shares during the last quarter. State Street Corp increased its holdings in Recursion Pharmaceuticals by 38.7% during the 4th quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after purchasing an additional 7,064,963 shares during the last quarter. Norges Bank acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $23,473,000. ARK Investment Management LLC raised its position in shares of Recursion Pharmaceuticals by 11.2% in the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after purchasing an additional 3,771,357 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG purchased a new position in shares of Recursion Pharmaceuticals during the 3rd quarter valued at approximately $7,954,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals News Roundup

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Q4 beat on EPS and revenue — Recursion reported narrower-than-expected Q4 loss (EPS -$0.21 vs. -$0.28 est.) and materially beat revenue estimates, driven partly by partner milestones. The results and upbeat metrics were the primary catalyst lifting the stock after the print. RXRX Q4 Loss Narrower Than Expected
• Positive Sentiment: Revenue jump / partner milestone extends runway — FY2025 revenue rose materially (reported ~$74.7M), with Roche-related milestone revenue cited as extending Recursion’s cash runway into 2028, reducing near-term financing risk. Recursion Q4 2025 Earnings Call Highlights
• Positive Sentiment: Clinical progress — Management highlighted advancement of programs (e.g., REC-4881 entering clinical stages), signalling the company is moving from discovery to clinical validation — a tangible de‑risking step for an AI-driven biotech. Recursion Hits Clinical Milestones
• Positive Sentiment: Analyst support — Needham reaffirmed a “buy” and set an $8 price target, giving investors a visible upside case and supporting momentum after the print. Needham Rating
• Neutral Sentiment: Earnings call emphasized strategy and partnerships — Management framed 2025 as a transition year (scale data + ML + clinical starts); useful for long-term thesis but not an immediate earnings driver. Earnings Call Summary
• Neutral Sentiment: Disclosure/analysis availability — Full call transcript and presentation were posted (useful for modelers and event traders). Earnings Presentation
• Negative Sentiment: Still unprofitable and wide negative margins — Despite the beat, Recursion remains loss-making (negative net margin/ROE) and analysts forecast negative FY EPS, leaving valuation and path to sustained profitability as open questions. AAII Analysis
• Negative Sentiment: Technical / liquidity headwinds — The stock traded below key moving averages with volume below its recent average, and remains volatile; those factors can pressure price even after positive news. Market Reaction

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.